Lymphocyte proliferation assay and cytokine profile in mixed specific dendritic cell/T cell lines to natural Bet V1 and wild type, chemical modified and genetically modified recombinant Bet V1

被引：0
|
作者：
Guida, G. [1 ]
Scirelli, T. [2 ]
Mistrello, G. [3 ]
Zanotta, S. [3 ]
Roncarolo, D. [3 ]
Bellone, G.
Rolla, G. [1 ]
机构：
[1] Univ Turin, ASO Mauriziano, Turin, Italy
[2] Univ Turin, Dipartimento Fisiopatol Clin, Mol Biol Lab, Turin, Italy
[3] Lofarma SPA, Milan, Italy
来源：
ALLERGY | 2008年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
482
引用
收藏
页码：190 / 190
页数：1
相关论文
共 11 条
  • [1] T-cell reactivity to natural and modified recombinant Bet v 1
    Wurtzen, PA
    Millner, A
    Holm, J
    Heinig, JH
    Jacobi, HH
    ALLERGY, 2002, 57 : 50 - 50
  • [2] Epicutaneous application of recombinant Bet v 1 and Bet v 1 derivatives induces allergen-specific IgG and T cell responses
    Campana, R.
    Moritz, K.
    Neubauer, A.
    Huber, H.
    Henning, R.
    Blatt, K.
    Hoermann, G.
    Brodie, T. M.
    Kaider, A.
    Valent, P.
    Sallusto, F.
    Woehrl, S.
    Valenta, R.
    EXPERIMENTAL DERMATOLOGY, 2014, 23 : 12 - 12
  • [3] Comparable T-cell activation induced by natural and recombinant Bet v 1
    Millner, A
    Wurtzen, PA
    Holm, J
    Heinig, JH
    Jacobi, HH
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S315 - S315
  • [4] Preserved epitope-specific T cell activation by recombinant Bet v 1-MBP fusion proteins
    Van Neerven, RJJ
    Sparholt, SH
    Schou, C
    Larsen, JN
    CLINICAL AND EXPERIMENTAL ALLERGY, 1998, 28 (04): : 423 - 433
  • [5] CHARACTERIZATION OF ALLERGEN (BET-V-1)-SPECIFIC T-CELL LINES AND CLONES FROM NONALLERGIC INDIVIDUALS
    EBNER, C
    SIEMANN, U
    NAJAFIAN, N
    SCHEINER, O
    KRAFT, D
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1995, 107 (1-3) : 183 - 185
  • [6] Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells
    Lisziewicz, J
    Gabrilovich, DI
    Varga, G
    Xu, JQ
    Greenberg, PD
    Arya, SK
    Bosch, M
    Behr, JP
    Lori, F
    JOURNAL OF VIROLOGY, 2001, 75 (16) : 7621 - 7628
  • [7] Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen, in a murine model of type I allergy
    Wiedermann, U
    Jahn-Schmid, B
    Bohle, B
    Repa, A
    Renz, H
    Kraft, D
    Ebner, C
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (06) : 1202 - 1210
  • [8] A recombinant bacterial cell surface (S-layer)-major birch pollen allergen-fusion protein (rSbsC/Bet v1) maintains the ability to self-assemble into regularly structured monomolecular lattices and the functionality of the allergen
    Breitwieser, A
    Egelseer, EM
    Moll, D
    Ilk, N
    Hotzy, C
    Bohle, B
    Ebner, C
    Sleytr, UB
    Sára, M
    PROTEIN ENGINEERING, 2002, 15 (03): : 243 - 249
  • [9] Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
    Hu, HM
    Urba, WJ
    Fox, BA
    JOURNAL OF IMMUNOLOGY, 1998, 161 (06): : 3033 - 3041
  • [10] IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro
    L Vujanovic
    E Ranieri
    A Gambotto
    W C Olson
    J M Kirkwood
    W J Storkus
    Cancer Gene Therapy, 2006, 13 : 798 - 805
12